Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors

• Status: Not yet recruiting
• Trial end date: 2026-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Neurosurgery is a risk factor for delirium. Dexmedetomidine might reduce delirium by reducing neuroinflammation, improving postoperative analgesia and sleep quality. The the primary hypothesis is that perioperative administration of dexmedetomidine can reduce the incidence of postoperative delirium

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Tiantan Hospital
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Patients with temporal glioma scheduled for a elective craniotomy

• Age ≥18 years

• Obtain written informed consent.

Exclusion Criteria:

• Patients with severe preoperative cognitive impairment

• History of traumatic brain injury or previous neurosurgery

• History of psychotropic medications

• Allergy to dexmedetomidine

• Pregnant or lactating women

• History of obstructive sleep apnoea syndrome

• Severe bradycardia(heart rate <40 beats/min), sick sinus syndrome or second-to-third degree atrioventricular block

• Severe hepatic dysfunction

• Severe renal dysfunction